{"gene":"NFIA","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2005,"finding":"NFI-A (NFIA) competes with C/EBPalpha for binding to the miR-223 promoter: NFIA maintains miR-223 at low levels, whereas C/EBPalpha replaces NFIA upon retinoic acid-induced differentiation to upregulate miR-223 expression. Additionally, miR-223 represses NFIA translation, forming a negative-feedback loop that controls granulopoiesis. RNAi against NFIA and ectopic miR-223 both enhance granulocytic differentiation in APL cells.","method":"Promoter competition assay, RNAi knockdown, ectopic expression, translational reporter assays in APL cells","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional experiments (RNAi, OE, reporter assays), multiple orthogonal methods in a single rigorous study, widely replicated","pmids":["16325577"],"is_preprint":false},{"year":2006,"finding":"NFIA is necessary and sufficient for induction of the glial marker GLAST in spinal cord ventricular zone progenitors, is required for continued inhibition of neurogenesis via HES5 (a Notch effector), and promotes migration and differentiation of astrocyte precursors. Loss of NFIA in the spinal cord prevents gliogenesis onset.","method":"In vivo loss-of-function (knockout mice), gain-of-function electroporation, immunofluorescence, gene expression analysis","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout plus gain-of-function with defined cellular and molecular phenotypes, replicated across labs","pmids":["17178400"],"is_preprint":false},{"year":1999,"finding":"Disruption of the murine Nfia gene causes agenesis of the corpus callosum and hydrocephalus, establishing NFIA as essential for corpus callosum formation and forebrain development.","method":"Gene knockout (homologous recombination), histology, behavioral assessment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined developmental phenotype, replicated by multiple subsequent studies","pmids":["10518556"],"is_preprint":false},{"year":2003,"finding":"NFIA is expressed in midline glial structures (glial wedge, indusium griseum, glial sling) of developing forebrain. In Nfia−/− mice, sling cells migrate aberrantly, midline glia are absent, Slit2 expression is reduced, and callosal axons fail to cross the midline, establishing NFIA as required for midline glia formation and commissural axon guidance.","method":"Immunohistochemistry, in situ hybridization, Nfia knockout mice, axon tracing","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct loss-of-function in KO mice with specific cellular and molecular phenotypes, multiple orthogonal methods","pmids":["12514217"],"is_preprint":false},{"year":2010,"finding":"NFIA downregulates the Notch effector Hes1 in telencephalic progenitors, thereby repressing progenitor self-renewal while simultaneously activating astrocyte-specific gene expression. NFIA thus links repression of self-renewal to activation of differentiation.","method":"Loss-of-function in vivo (Nfia KO mice), promoter reporter assays, gene expression analysis, chromatin immunoprecipitation","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mice combined with promoter assays and epistasis establishing NFIA→Hes1 repression, replicated across labs","pmids":["20610746"],"is_preprint":false},{"year":2012,"finding":"Sox9 induces NFIA expression to initiate gliogenesis. Sox9 and NFIA then form a protein complex and co-regulate downstream glial genes including Apcdd1 (migration) and Mmd2 (metabolism). This defines a Sox9→NFIA transcriptional cascade for glial lineage commitment.","method":"Co-immunoprecipitation, ChIP-seq, in vivo electroporation, loss-of-function mouse genetics, gene expression analysis","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP demonstrating Sox9-NFIA complex, ChIP-seq, in vivo genetics, multiple orthogonal methods","pmids":["22500632"],"is_preprint":false},{"year":2009,"finding":"NFIA directly binds and activates the beta-globin promoter while directly binding and repressing the G-CSF receptor promoter in hematopoietic progenitor cells, thereby directing progenitor fate toward the erythroid vs. granulocytic lineage.","method":"Chromatin immunoprecipitation, reporter assays, gain- and loss-of-function in unilineage and bilineage hematopoietic progenitor cultures","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct promoter binding (ChIP) combined with functional gain/loss-of-function assays showing lineage redirection","pmids":["19542302"],"is_preprint":false},{"year":2017,"finding":"NFIA co-localizes with PPARγ at brown-fat-specific enhancers; NFIA binding precedes and facilitates PPARγ binding, increasing chromatin accessibility and activating brown-fat gene transcription. NFIA-knockout brown fat shows impaired expression of brown-fat-specific genes and reciprocal elevation of muscle genes. Introduction of NFIA into myoblasts drives brown adipocyte differentiation.","method":"Genome-wide open chromatin analysis (ATAC-seq), ChIP-seq, NFIA knockout mice, lentiviral NFIA overexpression in myoblasts","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genome-wide chromatin analysis, KO mice, gain-of-function, multiple orthogonal methods in one study","pmids":["28812581"],"is_preprint":false},{"year":2020,"finding":"The C-terminal 17 amino acid residues of NFIA (pro#3 domain) are required for its transcriptional activity; this domain mediates chromatin penetration and binding to the Pparg enhancer to activate adipogenesis. Separately, a pro#3-domain-independent mechanism allows NFIA to bind the Myod1 enhancer and repress MyoD expression by competing with KLF5, suppressing the myogenic gene program.","method":"Deletion mutagenesis, ChIP-seq, NFIA-KO cell rescue experiments, reporter assays","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — domain mutagenesis combined with ChIP-seq and KO rescue, multiple orthogonal methods in single study","pmids":["32991581"],"is_preprint":false},{"year":2018,"finding":"NFIA promotes endocrine cell fate in pancreatic progenitors by transcriptionally repressing Mib1 (an E3 ubiquitin ligase targeting Dll1 for endocytosis), thereby limiting Dll1 internalization and restraining Notch activation to allow neurogenin-3 expression. Pancreatic deletion of NFIA increases duct and decreases endocrine formation; Mib1 knockdown rescues the cell fate defects.","method":"Pancreas-specific NFIA knockout mice, ectopic NFIA expression in human pancreatic progenitors, ChIP for NFIA binding at Mib1 promoter, Dll1 endocytosis assay, epistasis (Mib1 KD rescue)","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ChIP showing NFIA at Mib1 promoter, KO mice, human progenitor gain-of-function, genetic rescue epistasis","pmids":["30590051"],"is_preprint":false},{"year":2023,"finding":"NFIA in adipocytes upregulates oxidative phosphorylation genes by facilitating PPARγ genomic binding at enhancers and directly binds the regulatory region of the Ccl2 gene to repress MCP-1 transcription, thereby suppressing adipose tissue inflammation and improving glucose homeostasis.","method":"Adipocyte-specific NFIA transgenic mice, ChIP-seq, enhancer activation assays, glucose tolerance tests","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic model, ChIP-seq showing direct NFIA binding at Ccl2 regulatory region, multiple orthogonal methods","pmids":["37487068"],"is_preprint":false},{"year":2015,"finding":"During sepsis, NFIA transcriptionally represses the cyclin-dependent kinase inhibitor p21, arresting differentiation of Gr1+CD11b+ myeloid progenitors to generate immunosuppressive MDSCs. Knockdown of NFIA restores p21 expression and promotes monocyte/dendritic cell differentiation; ectopic NFIA in normal Gr1+CD11b+ cells generates an immunosuppressive phenotype.","method":"Gain- and loss-of-function (ectopic expression and siRNA knockdown), gene expression analysis, ex vivo differentiation assays in septic mouse myeloid cells","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional gain/loss-of-function with defined molecular target (p21), single lab, multiple assays","pmids":["26259914"],"is_preprint":false},{"year":2017,"finding":"Conditional myeloid-specific deletion of Nfia prevents MDSC expansion during sepsis; NFI-A-deficient Gr1+CD11b+ cells differentiate normally into macrophages and dendritic cells and are not immunosuppressive. Ectopic NFI-A expression in myeloid progenitors from Nfia-deficient mice restores MDSC phenotype. NFIA and miR-21/miR-181b form a mutual regulatory loop sustaining MDSC immunosuppression.","method":"Conditional myeloid knockout (LysM-Cre × Nfia-flox), ectopic NFI-A expression, ex vivo differentiation assays, cecal ligation and puncture sepsis model","journal":"Infection and immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with defined phenotype, gain-of-function rescue, replicated across multiple sepsis studies","pmids":["28167668"],"is_preprint":false},{"year":2004,"finding":"NFI-A proteins (identified via mass spectrometry after DNA-affinity purification from rat olfactory mucosa) bind the NPTA element in the CYP2A3 promoter and transactivate the gene in vitro. A novel alternative-splice isoform, NFI-A-short, lacks the transactivation domain and counteracts activation by full-length NFI-A2. ChIP demonstrates NFI association with the CYP2A3 promoter in olfactory mucosa but not in liver, where the promoter is hypermethylated.","method":"DNA-affinity purification, mass spectrometry, transient transfection reporter assay, chromatin immunoprecipitation (ChIP), alternative splicing analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution (reporter assay + mutagenesis-equivalent isoform comparison), ChIP in vivo, mass spec identification; single lab but multiple orthogonal methods","pmids":["15123731"],"is_preprint":false},{"year":2005,"finding":"NFI-A1 activates transcription through the CEREM enhancer element of the UGT1A2 promoter; NFI-C1 has an inhibitory effect and suppresses NFI-A1-mediated activation in a concentration-dependent manner through heterodimerization competition at CEREM.","method":"Affinity chromatography, immunoblot with isoform-specific antibodies, co-expression reporter gene assay in cultured hepatocytes","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assay with co-expression of NFI isoforms, single lab, two methods","pmids":["16169882"],"is_preprint":false},{"year":2016,"finding":"An NFIA:RAF1 fusion arising from chromosomal rearrangement results in constitutive Raf1 kinase activity, activates the MEK1/2 cascade, and promotes cancer cell proliferation. The NFIA:RAF1 fusion localizes to the plasma membrane (distinct from nuclear WT-NFIA and cytoplasmic WT-Raf1), indicating that NFIA sequences drive membrane targeting of the oncogenic fusion.","method":"RNA sequencing (fusion detection), kinase activity assay, MEK phosphorylation immunoblot, subcellular localization (immunofluorescence), cell proliferation assay","journal":"Cancer genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional kinase assay, subcellular localization, downstream signaling, single lab, multiple methods","pmids":["27810072"],"is_preprint":false},{"year":2017,"finding":"NFIA activates NFκB p65 transcription and protein levels in glioblastoma cells; NFκB in turn activates the NFIA promoter, forming a feed-forward loop. NFIA-driven NFκB activation is required for upregulation of anti-apoptotic factors TRAF1 and cIAPs. NFIA knockdown decreases NFκB and increases baseline apoptosis; NFκB inhibition reverses the NFIA anti-apoptotic effect.","method":"Gain- and loss-of-function (knockdown/overexpression), gene expression analysis, apoptosis assays, epistasis by NFκB inhibitor rescue in patient-derived GBM cells","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal transcriptional regulation established with functional epistasis, single lab, multiple orthogonal methods","pmids":["27994064"],"is_preprint":false},{"year":2017,"finding":"Sox9 and Isl1-Lhx3 regulate long-range enhancer activity to control NFIA expression in glial and neuronal populations in the spinal cord, respectively. These enhancers and transcription factors form distinct chromatin architectures (assessed by chromatin conformation analysis) in glial vs. neuronal lineages. In glioma models, the glia-specific chromatin architecture is preserved and these enhancers are required for NFIA expression and glioma formation.","method":"Enhancer reporter assays in vivo, chromatin conformation capture, genetic deletion of enhancers, glioma mouse models","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — chromatin conformation analysis, in vivo enhancer deletion, glioma functional studies; single lab but multiple orthogonal high-resolution methods","pmids":["28892058"],"is_preprint":false},{"year":2021,"finding":"NFIA directly regulates astrocytic TRPV4 expression; loss of NFIA inhibits TRPV4 upregulation, weakens astrocytic calcium activity and specific astrocyte reactivity, and suppresses seizure activity in a 4-AP epilepsy model. ChIP was used to identify NFIA binding at the TRPV4 regulatory region.","method":"RNAi knockdown of NFIA in vivo, NFIA overexpression (HA-tagged plasmid), ChIP for NFIA at TRPV4 promoter, calcium imaging, EEG seizure recording","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP showing NFIA at TRPV4 regulatory region, functional loss/gain-of-function with physiological readout, single lab","pmids":["37880726"],"is_preprint":false},{"year":2019,"finding":"Transient NFIA expression is sufficient to trigger glial competency of human pluripotent stem cell-derived neural stem cells within 5 days, involving rapid but reversible chromatin remodeling, GFAP promoter demethylation, and lengthening of the G1 cell cycle phase. Genetic or pharmacological G1 length manipulation partially mimics NFIA function.","method":"Lentiviral NFIA overexpression in human PSC-derived NSCs, ATAC-seq, bisulfite sequencing, cell cycle analysis, pharmacological G1 manipulation","journal":"Nature biotechnology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genome-wide chromatin remodeling assay, DNA methylation analysis, cell cycle experiments, functional differentiation assays, multiple orthogonal methods","pmids":["30804533"],"is_preprint":false},{"year":2021,"finding":"Sox8 is a direct transcriptional target of Nfia at the initiation of the gliogenic phase. Sox8 augments LIF-induced astrocytic differentiation by associating with STAT3 through transcriptional coactivator p300 (without inducing Gfap DNA demethylation, unlike Nfia itself). Sox8 knockdown inhibits Nfia-enhanced astrocytic differentiation.","method":"ChIP showing NFIA at Sox8 regulatory elements, Sox8 siRNA knockdown, Co-IP of Sox8 with STAT3 and p300, Gfap methylation analysis, differentiation assays","journal":"Pharmacology research & perspectives","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and Co-IP establishing direct regulatory relationship, single lab, multiple methods","pmids":["34677001"],"is_preprint":false},{"year":2023,"finding":"The NFIA-ETO2 fusion protein (from t(1;16)(p31;q24)) blocks erythroid differentiation by preferentially binding and repressing erythroid genes containing NFI binding sites and ETO2-decorated sites, shifting transcriptional activity from GATA- to ETS-motif-containing target genes. NFIA-ETO2 alone does not induce disease, but cooperates with TP53R248Q mutation to induce a fully penetrant transplantable pure erythroid leukemia in mice.","method":"Murine erythroblast retroviral expression, primary fetal liver EB cultures, transplantation assay, ChIP-seq, RNA-seq, motif analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq, RNA-seq, in vivo transplantation, genetic epistasis with TP53 mutation, multiple orthogonal methods","pmids":["36735909"],"is_preprint":false},{"year":2021,"finding":"NFIA and NFIB are co-expressed in developing cortex and can form heterodimers in vivo (demonstrated by co-immunoprecipitation). Compound homozygous knockout of both genes produces a more severe cortical phenotype than single knockouts, indicating additive function. Shared differentially regulated target genes are enriched for NFI binding sites in their promoters.","method":"Co-immunoprecipitation, compound knockout mouse genetics, RNA-seq, ChIP-seq","journal":"Brain and neuroscience advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrating heterodimerization, compound KO genetics, single lab, multiple methods","pmids":["32166136"],"is_preprint":false},{"year":2022,"finding":"The NFIA missense variant K125E is a loss-of-function allele: ectopic wild-type NFIA in Drosophila causes developmental defects not seen with K125E-NFIA; wild-type human NFIA rescues commissural axon defects in nfia-deficient zebrafish but K125E does not; K125E impairs transcriptional regulation of the HES1 promoter in cultured cells.","method":"Drosophila ectopic expression assay, zebrafish nfia morphant rescue, HES1 promoter luciferase reporter assay","journal":"American journal of medical genetics. Part A","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — two independent in vivo model organisms plus in vitro reporter assay, multiple orthogonal methods establishing LOF","pmids":["33973697"],"is_preprint":false},{"year":2025,"finding":"Crystal structures of NFIC homodimer and NFIA/NFIC monomers lacking their dimerization region in complex with double-stranded DNA reveal that NFI proteins recognize a dyad-symmetric TGGCA(N3)TGCCA sequence motif. Dimerization enhances both DNA-binding affinity and specificity. Mutagenesis and binding assays validate key residues in protein-DNA interaction. Disease-associated mutations are shown to impair DNA binding.","method":"X-ray crystallography, mutagenesis, in vitro DNA-binding affinity assays (EMSA/ITC), structural analysis","journal":"Acta biochimica et biophysica Sinica","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures of NFIA/NFIC-DNA complexes with mutagenesis validation; single study but Tier 1 methods with orthogonal binding assays","pmids":["41408833"],"is_preprint":false},{"year":2025,"finding":"In OA articular chondrocytes, NFIA upregulation drives increased fatty acid synthesis and oxidation by transcriptionally activating ACACA and CPT2. Inhibition of NFIA suppresses these metabolic enzymes and restores cellular homeostasis in murine and human OA chondrocytes.","method":"Multi-omics (RNA-seq, ATAC-seq, MRE-seq, metabolomics), NFIA inhibition in murine/human OA chondrocytes, gene expression analysis","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-omics linking NFIA to chromatin accessibility at metabolic gene loci, functional NFIA inhibition experiments, single study","pmids":["40737429"],"is_preprint":false},{"year":2025,"finding":"NFIA directly represses transcription of the glycolytic enzyme PKM in pancreatic cancer cells, thereby attenuating glycolysis. NFIA also transcriptionally suppresses FN1 expression. Loss of NFIA leads to increased glycolysis, histone lactylation, epigenetic upregulation of FN1, and activation of integrin α5β1-FAK-PI3K-Akt signaling.","method":"NFIA overexpression/knockdown, ChIP showing direct NFIA binding at PKM and FN1 promoters, glucose uptake/lactate assays, histone lactylation analysis, signaling pathway western blots","journal":"Apoptosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP at PKM and FN1 promoters, functional metabolic assays, single lab, multiple orthogonal methods","pmids":["41511661"],"is_preprint":false},{"year":2025,"finding":"NFIA directly binds two motifs in the SMC4 promoter (-1379 bp and -354 bp) to drive SMC4 transcription in glioma cells, as validated by dual-luciferase and ChIP assays. SMC4 promotes metastasis via TGF-β/SMAD signaling and aerobic glycolysis via LDHA.","method":"Dual-luciferase reporter assay, ChIP assay for NFIA at SMC4 promoter, NFIA and SMC4 gain/loss-of-function in glioma cell lines, xenograft and tail-vein metastasis models","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP and luciferase assay confirming NFIA-SMC4 promoter binding, functional downstream assays, single lab","pmids":["40933894"],"is_preprint":false},{"year":2025,"finding":"NFIA represses S100A7 expression by directly binding the S100A7 promoter (validated by ChIP and dual-luciferase assay), reducing inflammation and apoptosis of keratinocytes in oral lichen planus. NFIA overexpression ameliorates OLP inflammation in vivo, an effect reversed by S100A7 overexpression.","method":"ChIP assay, dual-luciferase reporter assay, shRNA knockdown, in vivo OLP mouse model, ELISA, flow cytometry","journal":"The Kaohsiung journal of medical sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP and luciferase establishing NFIA binding at S100A7 promoter, in vivo rescue experiments, single lab","pmids":["40560736"],"is_preprint":false},{"year":2022,"finding":"NFIA determines allele-specific Ucp1 expression in beige adipocytes: the alternative T allele of rs47238345 at the Ucp1 -12kb enhancer in 129 mice facilitates allele-specific NFIA binding, which mediates allele-specific enhancer-promoter looping and Ucp1 transcription. CRISPR-mediated SNP editing of rs47238345 increases Ucp1 expression.","method":"Allele-specific ChIP, chromatin conformation assay (enhancer-promoter interaction), CRISPR-Cas9/Cpf1 SNP editing, allele-specific expression analysis","journal":"iScience","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — allele-specific ChIP, chromatin looping assay, and CRISPR causal editing establish direct mechanistic link between NFIA binding and Ucp1 expression","pmids":["35874098"],"is_preprint":false},{"year":2023,"finding":"In Nfia conditional knockout retinas, AII amacrine cells are massively and selectively absent. Type 2 cone bipolar cells (which are interconnected to AII cells) are also partially reduced, with their loss occurring after AII cell loss, indicating a dependency relationship. Nfia loss results in profound diminishment of oscillatory potentials in the ERG.","method":"Conditional knockout mice (Nfia-CKO), cell counting, ERG electrophysiology, temporal deletion (postnatal)","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with precise temporal control, defined cellular and physiological phenotypes, epistasis between cell populations","pmids":["37775301"],"is_preprint":false},{"year":2023,"finding":"Astrocyte-derived extracellular vesicles (ADEVs) from obese/high-glucose-stimulated astrocytes are enriched in NFIA protein and are taken up by hippocampal neurons, causing synaptic injury and cognitive impairment. Astrocyte-specific knockdown of Nfia reduces NFIA in ADEVs and ameliorates synaptic dysfunction and cognitive impairment in obese mice.","method":"Proteomics of brain-derived EVs, AAV-mediated astrocyte-specific Nfia knockdown, ADEV isolation/administration, behavioral tests, synaptic protein analysis","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KD with defined behavioral/synaptic phenotype, proteomic identification, in vivo ADEV transfer experiments; single lab","pmids":["40448146"],"is_preprint":false},{"year":2024,"finding":"NFIA is required for motor neuron positioning, axonal branching, and neuromuscular junction formation in the spinal cord. NFIA is also required for proper mitochondrial function and ATP production in motor neurons, linking transcriptional regulation to metabolic function during motor circuit development.","method":"Conditional knockout mice, immunofluorescence, axon tracing, neuromuscular junction analysis, mitochondrial function assays (OCR/ATP production)","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined cellular and metabolic phenotypes; preprint, single lab","pmids":[],"is_preprint":true},{"year":2025,"finding":"CARM1 methylates NFIA (NFIA is a CARM1 substrate), and this CARM1/NFIA relationship represses NGFR signaling in glioma stem-like cells; loss of CARM1 dysregulates NFIA function and leads to increased NGFR/NTRK dependency.","method":"Multi-omics (proteomics + transcriptomics), CARM1 depletion, NFIA overexpression epistasis, NFIA-CARM1 substrate identification","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, single lab, substrate identification without in vitro reconstitution of methylation; mechanistic model proposed from indirect evidence","pmids":[],"is_preprint":true}],"current_model":"NFIA is a dimeric transcription factor that recognizes dyad-symmetric TGGCA(N3)TGCCA DNA motifs (established by crystal structure) and functions as a context-dependent transcriptional activator or repressor: in the nervous system it drives gliogenesis by activating glial genes, repressing the Notch effector Hes1, and forming a complex with Sox9; in adipose tissue it facilitates PPARγ binding at brown-fat enhancers to activate thermogenic and oxidative phosphorylation programs while directly repressing inflammatory genes such as Ccl2; in hematopoiesis it directly activates beta-globin and represses the G-CSF receptor to bias progenitors toward erythroid vs. granulocytic fate, and it sustains immunosuppressive MDSCs by repressing p21; in the pancreas it represses Mib1 to restrain Dll1 endocytosis and Notch activation, promoting endocrine fate; and in multiple cancers oncogenic NFIA fusions (NFIA-ETO2, NFIA-RAF1) drive disease through dominant gain-of-function mechanisms."},"narrative":{"mechanistic_narrative":"NFIA is a dimeric, sequence-specific transcription factor that acts as a context-dependent activator or repressor to control lineage commitment across the nervous system, blood, and adipose tissue [PMID:17178400, PMID:19542302, PMID:28812581]. It recognizes a dyad-symmetric TGGCA(N3)TGCCA motif, and dimerization enhances both its DNA-binding affinity and specificity [PMID:41408833]. In the developing CNS, NFIA is a master gliogenic switch: it is induced by Sox9 and forms a Sox9–NFIA protein complex to drive astrocyte gene programs, while repressing Notch effectors Hes1/Hes5 to terminate progenitor self-renewal and initiate differentiation [PMID:17178400, PMID:20610746, PMID:22500632]; its activity depends on long-range enhancers regulated by Sox9 and Isl1-Lhx3 [PMID:28892058], and transient NFIA expression alone confers glial competency through reversible chromatin remodeling and GFAP promoter demethylation [PMID:30804533]. Loss of NFIA in mice causes corpus callosum agenesis and hydrocephalus through failure of midline glia formation and commissural axon guidance, and a K125E loss-of-function variant impairs HES1 regulation and recapitulates these defects in model organisms [PMID:10518556, PMID:12514217, PMID:33973697]. In adipocytes, NFIA binds brown-fat and beige enhancers ahead of PPARγ to increase chromatin accessibility and activate thermogenic and oxidative-phosphorylation genes, while directly repressing the inflammatory chemokine gene Ccl2 [PMID:28812581, PMID:37487068, PMID:35874098]; a C-terminal pro#3 domain mediates this enhancer-penetrating activation, whereas a separate domain-independent mode lets NFIA repress Myod1 by competing with KLF5 [PMID:32991581]. In hematopoiesis NFIA biases progenitor fate by activating beta-globin and repressing the G-CSF receptor [PMID:19542302], and in pancreatic progenitors it represses the E3 ligase Mib1 to restrain Dll1 endocytosis and Notch activation, promoting endocrine fate [PMID:30590051]. NFIA also sustains immunosuppressive myeloid-derived suppressor cells during sepsis by repressing the cell-cycle inhibitor p21 [PMID:26259914, PMID:28167668]. In disease, oncogenic NFIA fusions act through gain-of-function: NFIA-RAF1 drives constitutive RAF/MEK signaling from the plasma membrane [PMID:27810072], and NFIA-ETO2 represses erythroid genes and cooperates with mutant TP53 to drive erythroleukemia [PMID:36735909].","teleology":[{"year":1999,"claim":"Established at the organismal level that NFIA is essential for forebrain development, defining a genetic requirement before its molecular targets were known.","evidence":"Nfia gene knockout in mice with histology and behavioral assessment","pmids":["10518556"],"confidence":"High","gaps":["Did not identify direct transcriptional targets","Cellular basis of the corpus callosum phenotype unresolved at this stage"]},{"year":2003,"claim":"Resolved the cellular basis of the developmental phenotype by showing NFIA is required for midline glia formation and Slit2-dependent commissural axon guidance.","evidence":"Immunohistochemistry, in situ hybridization, axon tracing in Nfia knockout mice","pmids":["12514217"],"confidence":"High","gaps":["Whether Slit2 is a direct NFIA target not established","Molecular mechanism of glial specification not yet defined"]},{"year":2004,"claim":"Identified NFIA biochemically as a sequence-specific transactivator and revealed isoform diversity, with a short splice variant lacking the transactivation domain acting as a dominant counter-regulator.","evidence":"DNA-affinity purification, mass spectrometry, reporter assays, and ChIP in rat olfactory mucosa","pmids":["15123731"],"confidence":"High","gaps":["Physiological role of NFI-A-short isoform in vivo unknown","Tissue-specific promoter methylation control of NFIA targets not generalized"]},{"year":2005,"claim":"Defined a mechanistic role for NFIA in granulopoiesis through a competitive promoter switch with C/EBPalpha and a miR-223 negative-feedback loop, framing NFIA as a tunable lineage gatekeeper.","evidence":"Promoter competition, RNAi, ectopic expression, and translational reporters in APL cells","pmids":["16325577"],"confidence":"High","gaps":["Did not address NFIA in erythroid fate","Structural basis of NFIA/C/EBPalpha competition not defined"]},{"year":2006,"claim":"Demonstrated NFIA is necessary and sufficient for gliogenesis onset, coupling glial gene activation to continued Notch-mediated repression of neurogenesis.","evidence":"In vivo knockout and gain-of-function electroporation in spinal cord progenitors","pmids":["17178400"],"confidence":"High","gaps":["Upstream inducers of NFIA not yet identified","Direct vs indirect regulation of HES5 unresolved"]},{"year":2009,"claim":"Showed NFIA directly and oppositely regulates two lineage promoters (beta-globin activation, G-CSFR repression) to redirect hematopoietic progenitor fate, establishing dual activator/repressor function on direct targets.","evidence":"ChIP, reporter assays, gain/loss-of-function in hematopoietic progenitor cultures","pmids":["19542302"],"confidence":"High","gaps":["Cofactors determining activation vs repression not identified","Chromatin context dictating bivalent behavior unknown"]},{"year":2010,"claim":"Unified NFIA's dual activity by showing it represses Hes1 to block self-renewal while activating astrocyte genes, linking the two arms of differentiation control.","evidence":"Nfia knockout mice, promoter reporters, and ChIP in telencephalic progenitors","pmids":["20610746"],"confidence":"High","gaps":["Mechanism distinguishing repressive vs activating complexes not defined"]},{"year":2012,"claim":"Placed NFIA in a Sox9→NFIA cascade and demonstrated direct Sox9–NFIA complex formation co-regulating glial migration and metabolic genes.","evidence":"Co-IP, ChIP-seq, in vivo electroporation, and mouse genetics","pmids":["22500632"],"confidence":"High","gaps":["Structural details of the Sox9-NFIA interface unknown","Genome-wide division of labor between Sox9 and NFIA incomplete"]},{"year":2015,"claim":"Extended NFIA's repressor role to innate immunity, showing it represses p21 to arrest myeloid differentiation and generate immunosuppressive MDSCs during sepsis.","evidence":"Gain/loss-of-function and ex vivo differentiation in septic mouse myeloid cells","pmids":["26259914"],"confidence":"Medium","gaps":["Single-lab functional data without in vivo conditional deletion at this stage","Direct ChIP at p21 promoter not shown here"]},{"year":2017,"claim":"Established NFIA as a pioneer-like factor in brown fat that binds enhancers ahead of PPARγ to open chromatin and activate the thermogenic program, demonstrating a chromatin-priming mechanism.","evidence":"ATAC-seq, ChIP-seq, knockout mice, and myoblast overexpression","pmids":["28812581"],"confidence":"High","gaps":["Whether NFIA binds nucleosomal DNA as a bona fide pioneer factor not directly tested","Cofactors recruited to open enhancers undefined"]},{"year":2017,"claim":"Confirmed and mechanistically anchored the MDSC role with myeloid-specific conditional deletion and a NFIA–miR-21/miR-181b regulatory loop sustaining immunosuppression.","evidence":"LysM-Cre × Nfia-flox conditional knockout, rescue, and CLP sepsis model","pmids":["28167668"],"confidence":"High","gaps":["Direct microRNA-NFIA promoter interactions not fully mapped"]},{"year":2017,"claim":"Revealed lineage-specific long-range enhancer architecture controlling NFIA expression in glia versus neurons, and showed glioma exploits the glial enhancer configuration.","evidence":"In vivo enhancer reporters, chromatin conformation capture, enhancer deletion, glioma mouse models","pmids":["28892058"],"confidence":"High","gaps":["How Sox9 vs Isl1-Lhx3 select distinct enhancers not resolved"]},{"year":2017,"claim":"Identified an NFIA-driven feed-forward NFκB loop conferring anti-apoptotic survival in glioblastoma, expanding NFIA into a pro-tumor transcriptional circuit.","evidence":"Knockdown/overexpression, apoptosis assays, and NFκB inhibitor epistasis in patient-derived GBM cells","pmids":["27994064"],"confidence":"Medium","gaps":["Whether NFIA binds the p65 promoter directly not shown","Single-lab study"]},{"year":2018,"claim":"Defined a non-cell-autonomous Notch control mechanism whereby NFIA represses Mib1 to limit Dll1 endocytosis and promote pancreatic endocrine fate, with genetic rescue establishing causality.","evidence":"Pancreas-specific knockout, human progenitor gain-of-function, ChIP, and Mib1-knockdown epistasis","pmids":["30590051"],"confidence":"High","gaps":["Cofactors mediating Mib1 repression not identified"]},{"year":2019,"claim":"Demonstrated NFIA is sufficient to confer human glial competency via rapid reversible chromatin remodeling, GFAP demethylation, and G1 lengthening, linking cell-cycle state to epigenetic licensing.","evidence":"Lentiviral NFIA in human PSC-derived NSCs, ATAC-seq, bisulfite sequencing, cell-cycle and pharmacological assays","pmids":["30804533"],"confidence":"High","gaps":["Causal chain between G1 lengthening and chromatin opening incompletely separated","How NFIA directs demethylation machinery unknown"]},{"year":2020,"claim":"Mapped distinct domains for NFIA's opposing activities: a C-terminal pro#3 domain for enhancer-penetrating activation of Pparg, and a domain-independent KLF5-competitive mechanism for Myod1 repression.","evidence":"Deletion mutagenesis, ChIP-seq, and knockout rescue in adipogenic cells","pmids":["32991581"],"confidence":"High","gaps":["Structural basis of chromatin penetration by pro#3 domain unknown"]},{"year":2021,"claim":"Showed NFIA forms heterodimers with NFIB in cortex and acts additively, indicating combinatorial NFI control of shared targets.","evidence":"Co-IP, compound knockout genetics, RNA-seq, ChIP-seq","pmids":["32166136"],"confidence":"Medium","gaps":["Functional consequences of heterodimer vs homodimer not separated","Single-lab data"]},{"year":2021,"claim":"Identified Sox8 as a direct NFIA target that amplifies astrocytic differentiation through STAT3/p300, extending the gliogenic cascade downstream of NFIA.","evidence":"ChIP, Sox8 knockdown, Co-IP of Sox8 with STAT3/p300, methylation analysis","pmids":["34677001"],"confidence":"Medium","gaps":["Single-lab study","Relative contribution of Sox8 vs other targets to gliogenesis unquantified"]},{"year":2021,"claim":"Linked NFIA to astrocyte physiology by showing it directly regulates TRPV4 to control astrocytic calcium activity and seizure susceptibility.","evidence":"In vivo RNAi/overexpression, ChIP, calcium imaging, EEG in a 4-AP epilepsy model","pmids":["37880726"],"confidence":"Medium","gaps":["Single-lab study","Whether the effect is purely transcriptional not fully isolated"]},{"year":2022,"claim":"Established NFIA K125E as a disease-causing loss-of-function allele through cross-species rescue failure and impaired HES1 regulation, connecting NFIA dysfunction to human developmental disease.","evidence":"Drosophila ectopic expression, zebrafish morphant rescue, HES1 luciferase reporter","pmids":["33973697"],"confidence":"High","gaps":["Full spectrum of patient phenotypes not mechanistically mapped","Structural impact of K125E on DNA binding not resolved here"]},{"year":2022,"claim":"Provided causal evidence that allele-specific NFIA binding at a Ucp1 enhancer SNP controls enhancer-promoter looping and thermogenic gene expression, demonstrating NFIA's role in 3D enhancer regulation.","evidence":"Allele-specific ChIP, chromatin conformation, CRISPR SNP editing in beige adipocytes","pmids":["35874098"],"confidence":"High","gaps":["Looping machinery recruited by NFIA not identified"]},{"year":2023,"claim":"Defined the NFIA-ETO2 fusion oncomechanism, showing it redirects transcription from GATA to ETS targets and cooperates with mutant TP53 to drive pure erythroleukemia.","evidence":"Murine erythroblast expression, ChIP-seq, RNA-seq, transplantation, TP53 epistasis","pmids":["36735909"],"confidence":"High","gaps":["Whether the fusion's repressive activity requires native NFIA partners unclear"]},{"year":2023,"claim":"Showed NFIA improves metabolic homeostasis in adipose tissue by facilitating PPARγ-driven oxidative phosphorylation genes and directly repressing the inflammatory chemokine Ccl2.","evidence":"Adipocyte-specific transgenic mice, ChIP-seq, glucose tolerance tests","pmids":["37487068"],"confidence":"High","gaps":["Cofactors mediating Ccl2 repression not identified"]},{"year":2023,"claim":"Revealed a selective cell-type requirement for NFIA in retinal AII amacrine cell generation, with dependent loss of interconnected bipolar cells and impaired retinal physiology.","evidence":"Temporally controlled conditional knockout, cell counting, ERG","pmids":["37775301"],"confidence":"High","gaps":["Direct retinal NFIA targets not identified"]},{"year":2025,"claim":"Provided the structural basis for NFI DNA recognition, showing dyad-symmetric motif binding and dimerization-enhanced affinity/specificity, and rationalizing how disease mutations impair DNA binding.","evidence":"X-ray crystallography of NFIA/NFIC-DNA complexes with mutagenesis and binding assays","pmids":["41408833"],"confidence":"High","gaps":["Full-length NFIA structure with transactivation domains not determined","Structures with cofactors absent"]},{"year":2025,"claim":"Expanded NFIA into metabolic regulation in disease, showing it controls fatty acid metabolism in osteoarthritic chondrocytes and represses glycolysis/FN1 in pancreatic cancer.","evidence":"Multi-omics and NFIA inhibition in OA chondrocytes; ChIP and metabolic assays in pancreatic cancer cells","pmids":["40737429","41511661"],"confidence":"Medium","gaps":["Context-dependent direction of metabolic regulation not reconciled","Single-lab studies"]},{"year":null,"claim":"How NFIA's bidirectional activator/repressor output is selected at each locus — through specific cofactor recruitment, post-translational modification, and chromatin context — remains incompletely defined.","evidence":"No single study in the corpus resolves the cofactor/modification code governing activation vs repression","pmids":[],"confidence":"Low","gaps":["Cofactor partners that toggle NFIA between activation and repression unidentified","Role of post-translational modification (e.g. methylation) in activity switching unproven","Genome-wide rules predicting target outcome lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,4,6,7,8,9,10,24]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[24,6,9,29]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[15,5]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,2,3,4,5,30]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,9,10,24]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[7,19,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[15,21,23]}],"complexes":[],"partners":["SOX9","NFIB","PPARG","NFIC"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q12857","full_name":"Nuclear factor 1 A-type","aliases":["CCAAT-box-binding transcription factor","CTF","Nuclear factor I/A","NF-I/A","NFI-A","TGGCA-binding protein"],"length_aa":509,"mass_kda":55.9,"function":"Recognizes and binds the palindromic sequence 5'-TTGGCNNNNNGCCAA-3' present in viral and cellular promoters and in the origin of replication of adenovirus type 2. These proteins are individually capable of activating transcription and replication","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q12857/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NFIA","classification":"Not Classified","n_dependent_lines":18,"n_total_lines":1208,"dependency_fraction":0.014900662251655629},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NFIA","total_profiled":1310},"omim":[{"mim_id":"613735","title":"BRAIN MALFORMATIONS WITH OR WITHOUT URINARY TRACT DEFECTS; BRMUTD","url":"https://www.omim.org/entry/613735"},{"mim_id":"600729","title":"NUCLEAR FACTOR I/C; NFIC","url":"https://www.omim.org/entry/600729"},{"mim_id":"600728","title":"NUCLEAR FACTOR I/B; NFIB","url":"https://www.omim.org/entry/600728"},{"mim_id":"600727","title":"NUCLEAR FACTOR I/A; NFIA","url":"https://www.omim.org/entry/600727"},{"mim_id":"600715","title":"THROMBOSPONDIN IV; THBS4","url":"https://www.omim.org/entry/600715"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NFIA"},"hgnc":{"alias_symbol":["NFI-L","KIAA1439"],"prev_symbol":[]},"alphafold":{"accession":"Q12857","domains":[{"cath_id":"3.90.520.10","chopping":"3-174","consensus_level":"high","plddt":92.0966,"start":3,"end":174}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12857","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q12857-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q12857-F1-predicted_aligned_error_v6.png","plddt_mean":62.72},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NFIA","jax_strain_url":"https://www.jax.org/strain/search?query=NFIA"},"sequence":{"accession":"Q12857","fasta_url":"https://rest.uniprot.org/uniprotkb/Q12857.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q12857/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12857"}},"corpus_meta":[{"pmid":"16325577","id":"PMC_16325577","title":"A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16325577","citation_count":822,"is_preprint":false},{"pmid":"17178400","id":"PMC_17178400","title":"The transcription factor NFIA controls the onset of gliogenesis in the developing spinal cord.","date":"2006","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/17178400","citation_count":401,"is_preprint":false},{"pmid":"22500632","id":"PMC_22500632","title":"Sox9 and NFIA coordinate a transcriptional regulatory cascade during the initiation of gliogenesis.","date":"2012","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/22500632","citation_count":292,"is_preprint":false},{"pmid":"10518556","id":"PMC_10518556","title":"Disruption of the murine nuclear factor I-A gene (Nfia) results in perinatal lethality, hydrocephalus, and agenesis of the corpus callosum.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10518556","citation_count":196,"is_preprint":false},{"pmid":"30804533","id":"PMC_30804533","title":"NFIA is a gliogenic switch enabling rapid derivation of functional human astrocytes from pluripotent stem cells.","date":"2019","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/30804533","citation_count":180,"is_preprint":false},{"pmid":"2339052","id":"PMC_2339052","title":"Chicken NFI/TGGCA proteins are encoded by at least three independent genes: NFI-A, NFI-B and NFI-C with homologues in mammalian genomes.","date":"1990","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2339052","citation_count":172,"is_preprint":false},{"pmid":"12514217","id":"PMC_12514217","title":"Abnormal development of forebrain midline glia and commissural projections in Nfia knock-out mice.","date":"2003","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12514217","citation_count":172,"is_preprint":false},{"pmid":"25265644","id":"PMC_25265644","title":"RP5-833A20.1/miR-382-5p/NFIA-dependent signal transduction pathway contributes to the regulation of cholesterol homeostasis and inflammatory reaction.","date":"2014","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25265644","citation_count":163,"is_preprint":false},{"pmid":"20610746","id":"PMC_20610746","title":"NFIA controls telencephalic progenitor cell differentiation through repression of the Notch effector Hes1.","date":"2010","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20610746","citation_count":123,"is_preprint":false},{"pmid":"17530927","id":"PMC_17530927","title":"NFIA haploinsufficiency is associated with a CNS malformation syndrome and urinary tract defects.","date":"2007","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17530927","citation_count":109,"is_preprint":false},{"pmid":"24980967","id":"PMC_24980967","title":"MicroRNA 21 (miR-21) and miR-181b couple with NFI-A to generate myeloid-derived suppressor cells and promote immunosuppression in late sepsis.","date":"2014","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24980967","citation_count":96,"is_preprint":false},{"pmid":"28812581","id":"PMC_28812581","title":"NFIA co-localizes with PPARγ and transcriptionally controls the brown fat gene program.","date":"2017","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28812581","citation_count":87,"is_preprint":false},{"pmid":"7590749","id":"PMC_7590749","title":"Chromosomal localization of the four genes (NFIA, B, C, and X) for the human transcription factor nuclear factor I by FISH.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7590749","citation_count":72,"is_preprint":false},{"pmid":"33794884","id":"PMC_33794884","title":"Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33794884","citation_count":62,"is_preprint":false},{"pmid":"33815662","id":"PMC_33815662","title":"Exosomal circEhmt1 Released from Hypoxia-Pretreated Pericytes Regulates High Glucose-Induced Microvascular Dysfunction via the NFIA/NLRP3 Pathway.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/33815662","citation_count":57,"is_preprint":false},{"pmid":"19542302","id":"PMC_19542302","title":"NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19542302","citation_count":55,"is_preprint":false},{"pmid":"33144585","id":"PMC_33144585","title":"MiRNA-671-5p Promotes prostate cancer development and metastasis by targeting NFIA/CRYAB axis.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33144585","citation_count":43,"is_preprint":false},{"pmid":"28892058","id":"PMC_28892058","title":"Glia-specific enhancers and chromatin structure regulate NFIA expression and glioma tumorigenesis.","date":"2017","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28892058","citation_count":41,"is_preprint":false},{"pmid":"24462883","id":"PMC_24462883","title":"An intragenic deletion of the NFIA gene in a patient with a hypoplastic corpus callosum, craniofacial abnormalities and urinary tract defects.","date":"2014","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24462883","citation_count":37,"is_preprint":false},{"pmid":"19763616","id":"PMC_19763616","title":"A novel 1p31.3p32.2 deletion involving the NFIA gene detected by array CGH in a patient with macrocephaly and hypoplasia of the corpus callosum.","date":"2009","source":"European journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/19763616","citation_count":36,"is_preprint":false},{"pmid":"27810072","id":"PMC_27810072","title":"A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma.","date":"2016","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27810072","citation_count":32,"is_preprint":false},{"pmid":"31838646","id":"PMC_31838646","title":"Common Regulatory Targets of NFIA, NFIX and NFIB during Postnatal Cerebellar Development.","date":"2020","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31838646","citation_count":31,"is_preprint":false},{"pmid":"27994064","id":"PMC_27994064","title":"A novel NFIA-NFκB feed-forward loop contributes to glioblastoma cell survival.","date":"2017","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27994064","citation_count":30,"is_preprint":false},{"pmid":"22030051","id":"PMC_22030051","title":"Chromosome 1p32-p31 deletion syndrome: prenatal diagnosis by array comparative genomic hybridization using uncultured amniocytes and association with NFIA haploinsufficiency, ventriculomegaly, corpus callosum hypogenesis, abnormal external genitalia, and intrauterine growth restriction.","date":"2011","source":"Taiwanese journal of obstetrics & gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/22030051","citation_count":29,"is_preprint":false},{"pmid":"28075452","id":"PMC_28075452","title":"A novel pathway in NSCLC cells: miR‑191, targeting NFIA, is induced by chronic hypoxia, and promotes cell proliferation and migration.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28075452","citation_count":28,"is_preprint":false},{"pmid":"26405609","id":"PMC_26405609","title":"Particulate β-glucan regulates the immunosuppression of granulocytic myeloid-derived suppressor cells by inhibiting NFIA expression.","date":"2015","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/26405609","citation_count":28,"is_preprint":false},{"pmid":"32166136","id":"PMC_32166136","title":"Combined allelic dosage of Nfia and Nfib regulates cortical development.","date":"2017","source":"Brain and neuroscience advances","url":"https://pubmed.ncbi.nlm.nih.gov/32166136","citation_count":27,"is_preprint":false},{"pmid":"27081522","id":"PMC_27081522","title":"Truncating mutation in NFIA causes brain malformation and urinary tract defects.","date":"2015","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/27081522","citation_count":27,"is_preprint":false},{"pmid":"32991581","id":"PMC_32991581","title":"NFIA differentially controls adipogenic and myogenic gene program through distinct pathways to ensure brown and beige adipocyte differentiation.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32991581","citation_count":25,"is_preprint":false},{"pmid":"37487068","id":"PMC_37487068","title":"NFIA in adipocytes reciprocally regulates mitochondrial and inflammatory gene program to improve glucose homeostasis.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37487068","citation_count":23,"is_preprint":false},{"pmid":"28167668","id":"PMC_28167668","title":"Myeloid Cell-Specific Knockout of NFI-A Improves Sepsis Survival.","date":"2017","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28167668","citation_count":22,"is_preprint":false},{"pmid":"34677001","id":"PMC_34677001","title":"SoxE group transcription factor Sox8 promotes astrocytic differentiation of neural stem/precursor cells downstream of Nfia.","date":"2021","source":"Pharmacology research & perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/34677001","citation_count":22,"is_preprint":false},{"pmid":"31365782","id":"PMC_31365782","title":"MiR-424 prevents astrogliosis after cerebral ischemia/reperfusion in elderly mice by enhancing repressive H3K27me3 via NFIA/DNMT1 signaling.","date":"2019","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/31365782","citation_count":22,"is_preprint":false},{"pmid":"32779154","id":"PMC_32779154","title":"LncRNA NFIA-AS2 promotes glioma progression through modulating the miR-655-3p/ZFX axis.","date":"2020","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/32779154","citation_count":21,"is_preprint":false},{"pmid":"26259914","id":"PMC_26259914","title":"NFI-A disrupts myeloid cell differentiation and maturation in septic mice.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26259914","citation_count":20,"is_preprint":false},{"pmid":"31760595","id":"PMC_31760595","title":"Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma.","date":"2019","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31760595","citation_count":20,"is_preprint":false},{"pmid":"27779670","id":"PMC_27779670","title":"Long non-coding RNA RP5-833A20.1 inhibits proliferation, metastasis and cell cycle progression by suppressing the expression of NFIA in U251 cells.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/27779670","citation_count":20,"is_preprint":false},{"pmid":"28941020","id":"PMC_28941020","title":"Loss-of-function variants in NFIA provide further support that NFIA is a critical gene in 1p32-p31 deletion syndrome: A four patient series.","date":"2017","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/28941020","citation_count":20,"is_preprint":false},{"pmid":"33536761","id":"PMC_33536761","title":"LncRNA LINC00511 Acts as an Oncogene in Colorectal Cancer via Sponging miR-29c-3p to Upregulate NFIA.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33536761","citation_count":20,"is_preprint":false},{"pmid":"25435940","id":"PMC_25435940","title":"miR-29a activates Hes1 by targeting Nfia in esophageal carcinoma cell line TE-1.","date":"2014","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/25435940","citation_count":19,"is_preprint":false},{"pmid":"15123731","id":"PMC_15123731","title":"Transcriptional regulation of rat CYP2A3 by nuclear factor 1: identification of a novel NFI-A isoform, and evidence for tissue-selective interaction of NFI with the CYP2A3 promoter in vivo.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15123731","citation_count":19,"is_preprint":false},{"pmid":"26997977","id":"PMC_26997977","title":"Comparative deletion mapping at 1p31.3-p32.2 implies NFIA responsible for intellectual disability coupled with macrocephaly and the presence of several other genes for syndromic intellectual disability.","date":"2016","source":"Molecular cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/26997977","citation_count":19,"is_preprint":false},{"pmid":"29172874","id":"PMC_29172874","title":"Nfia deletion in myeloid cells blocks expansion of myeloid-derived suppressor cells during sepsis.","date":"2017","source":"Innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29172874","citation_count":18,"is_preprint":false},{"pmid":"37880726","id":"PMC_37880726","title":"Cell-specific NFIA upregulation promotes epileptogenesis by TRPV4-mediated astrocyte reactivity.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37880726","citation_count":17,"is_preprint":false},{"pmid":"32840181","id":"PMC_32840181","title":"MALAT1 overexpression attenuates AS by inhibiting ox-LDL-stimulated dendritic cell maturation via miR-155-5p/NFIA axis.","date":"2020","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/32840181","citation_count":17,"is_preprint":false},{"pmid":"33313700","id":"PMC_33313700","title":"Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 Translocation in an Infant Erythroblastic Sarcoma.","date":"2021","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33313700","citation_count":17,"is_preprint":false},{"pmid":"24560411","id":"PMC_24560411","title":"The nuclear factor I/A (NFIA) gene is associated with the asthma plus rhinitis phenotype.","date":"2014","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24560411","citation_count":16,"is_preprint":false},{"pmid":"30590051","id":"PMC_30590051","title":"Pancreatic Cell Fate Determination Relies on Notch Ligand Trafficking by NFIA.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30590051","citation_count":16,"is_preprint":false},{"pmid":"29071714","id":"PMC_29071714","title":"DNER and NFIA are expressed by developing and mature AII amacrine cells in the mouse retina.","date":"2017","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29071714","citation_count":14,"is_preprint":false},{"pmid":"33640202","id":"PMC_33640202","title":"Genome-wide association study identifies susceptibility loci of brain atrophy to NFIA and ST18 in Alzheimer's disease.","date":"2021","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/33640202","citation_count":14,"is_preprint":false},{"pmid":"33346791","id":"PMC_33346791","title":"NFIA and NFIB function as tumour suppressors in high-grade glioma in mice.","date":"2021","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/33346791","citation_count":12,"is_preprint":false},{"pmid":"26021864","id":"PMC_26021864","title":"PAX6 does not regulate Nfia and Nfib expression during neocortical development.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26021864","citation_count":11,"is_preprint":false},{"pmid":"37315400","id":"PMC_37315400","title":"SOX9/NFIA promotes human ovarian cancer metastasis through the Wnt/β-catenin signaling pathway.","date":"2023","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/37315400","citation_count":11,"is_preprint":false},{"pmid":"33973697","id":"PMC_33973697","title":"Recurrent NFIA K125E substitution represents a loss-of-function allele: Sensitive in vitro and in vivo assays for nontruncating alleles.","date":"2021","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/33973697","citation_count":11,"is_preprint":false},{"pmid":"26329426","id":"PMC_26329426","title":"TNF-α-mediated microRNA-136 induces differentiation of myeloid cells by targeting NFIA.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26329426","citation_count":11,"is_preprint":false},{"pmid":"38680232","id":"PMC_38680232","title":"Association of ARRDC3 and NFIA variants with bovine congestive heart failure in feedlot cattle.","date":"2024","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/38680232","citation_count":10,"is_preprint":false},{"pmid":"36735909","id":"PMC_36735909","title":"The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36735909","citation_count":10,"is_preprint":false},{"pmid":"31178144","id":"PMC_31178144","title":"A novel role for NFIA in restoring radiosensitivity in radioresistant NSCLC cells by downregulating the AKT and ERK pathways.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31178144","citation_count":10,"is_preprint":false},{"pmid":"35622109","id":"PMC_35622109","title":"HIF-1α and NFIA-AS2 Polymorphisms as Potential Determinants of Total Hemoglobin Mass in Endurance Athletes.","date":"2020","source":"Journal of strength and conditioning research","url":"https://pubmed.ncbi.nlm.nih.gov/35622109","citation_count":9,"is_preprint":false},{"pmid":"40024453","id":"PMC_40024453","title":"Aqueous extract of Rehmanniae Radix Praeparata improves bone health in ovariectomized rats by modulating the miR-29a-3p/NFIA/Wnt signaling pathway axis.","date":"2025","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40024453","citation_count":9,"is_preprint":false},{"pmid":"32926563","id":"PMC_32926563","title":"A novel NFIA gene nonsense mutation in a Chinese patient with macrocephaly, corpus callosum hypoplasia, developmental delay, and dysmorphic features.","date":"2020","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32926563","citation_count":9,"is_preprint":false},{"pmid":"16169882","id":"PMC_16169882","title":"Transcriptional enhancement of UDP-glucuronosyltransferase form 1A2 (UGT1A2) by nuclear factor I-A (NFI-A) in rat hepatocytes.","date":"2005","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16169882","citation_count":9,"is_preprint":false},{"pmid":"40737429","id":"PMC_40737429","title":"NFIA regulates articular chondrocyte fatty acid metabolism and joint homeostasis.","date":"2025","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40737429","citation_count":7,"is_preprint":false},{"pmid":"36254157","id":"PMC_36254157","title":"miR-181d-5p Protects against Retinal Ganglion Cell Death after Blunt Ocular Injury by Regulating NFIA-Medicated Astrocyte Development.","date":"2022","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/36254157","citation_count":7,"is_preprint":false},{"pmid":"36553517","id":"PMC_36553517","title":"Phenotypic Spectrum of NFIA Haploinsufficiency: Two Additional Cases and Review of the Literature.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36553517","citation_count":6,"is_preprint":false},{"pmid":"35271849","id":"PMC_35271849","title":"An miRNA derived from amelogenin exon4 regulates expression of transcription factor Runx2 by directly targeting upstream activators Nfia and Prkch.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35271849","citation_count":6,"is_preprint":false},{"pmid":"37775301","id":"PMC_37775301","title":"Nfia Is Critical for AII Amacrine Cell Production: Selective Bipolar Cell Dependencies and Diminished ERG.","date":"2023","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37775301","citation_count":5,"is_preprint":false},{"pmid":"35018717","id":"PMC_35018717","title":"The p.Thr395Met missense variant of NFIA found in a patient with intellectual disability is a defective variant.","date":"2022","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/35018717","citation_count":5,"is_preprint":false},{"pmid":"35874098","id":"PMC_35874098","title":"NFIA determines the cis-effect of genetic variation on Ucp1 expression in murine thermogenic adipocytes.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35874098","citation_count":5,"is_preprint":false},{"pmid":"34324178","id":"PMC_34324178","title":"Direct Cell Reprogramming of Mouse Fibroblasts into Functional Astrocytes Using Lentiviral Overexpression of the Transcription Factors NFIA, NFIB, and SOX9.","date":"2021","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/34324178","citation_count":5,"is_preprint":false},{"pmid":"37056786","id":"PMC_37056786","title":"Inhibition of lncRNA NFIA-AS1 Alleviates Abnormal Proliferation and Inflammation of Vascular Smooth Muscle Cells in Atherosclerosis by Regulating miR-125a-3p/AKT1 Axis.","date":"2023","source":"International journal of genomics","url":"https://pubmed.ncbi.nlm.nih.gov/37056786","citation_count":5,"is_preprint":false},{"pmid":"32068188","id":"PMC_32068188","title":"Expression of NFIA and NFIB within the murine spinal cord.","date":"2020","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/32068188","citation_count":4,"is_preprint":false},{"pmid":"40448146","id":"PMC_40448146","title":"Astrocyte-derived extracellular vesicular NFIA mediates obesity-associated cognitive impairment.","date":"2025","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/40448146","citation_count":3,"is_preprint":false},{"pmid":"39546395","id":"PMC_39546395","title":"Generating iAstrocytes From Human Induced Pluripotent Stem Cells by Combining Low-Density Passaging of Neural Progenitor Cells and Transcription Factor NFIA Transdifferentiation.","date":"2024","source":"Current protocols","url":"https://pubmed.ncbi.nlm.nih.gov/39546395","citation_count":3,"is_preprint":false},{"pmid":"38243303","id":"PMC_38243303","title":"CNS erythroblastic sarcoma: a potential emerging pediatric tumor type characterized by NFIA::RUNX1T1/3 fusions.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/38243303","citation_count":3,"is_preprint":false},{"pmid":"35006644","id":"PMC_35006644","title":"Pathogenic variant in NFIA associated with subdural hematomas mimicking nonaccidental trauma.","date":"2022","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/35006644","citation_count":3,"is_preprint":false},{"pmid":"38188845","id":"PMC_38188845","title":"Significant phenotypic variability in a multigenerational family with an NFIA missense mutation: Case series and review of the literature.","date":"2024","source":"Clinical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/38188845","citation_count":3,"is_preprint":false},{"pmid":"40581369","id":"PMC_40581369","title":"Transcriptional control of brown adipocyte differentiation and function by NFIA: recent perspectives on deciphering metabolic diseases.","date":"2025","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40581369","citation_count":2,"is_preprint":false},{"pmid":"38884198","id":"PMC_38884198","title":"Pediatric Erythroid Sarcoma Diagnostically Confirmed by Identification of a Recurrent NFIA::CBFA2T3 Fusion.","date":"2024","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38884198","citation_count":2,"is_preprint":false},{"pmid":"40560736","id":"PMC_40560736","title":"Deletion of NFIA Leads to Activation of S100A7 and Inflammatory Response-Induced Apoptosis of Keratinocytes in Oral Lichen Planus Progression.","date":"2025","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40560736","citation_count":2,"is_preprint":false},{"pmid":"36806387","id":"PMC_36806387","title":"Identification and characterization of the long non-coding RNA NFIA-AS2 as a novel locus for body mass index in American Indians.","date":"2023","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/36806387","citation_count":1,"is_preprint":false},{"pmid":"32553203","id":"PMC_32553203","title":"Overseeing Memory Circuits by NFIA: New Face In Astrocytes.","date":"2020","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/32553203","citation_count":1,"is_preprint":false},{"pmid":"40933894","id":"PMC_40933894","title":"NFIA-dependent upregulation of SMC4 promotes metastasis and metabolic reprogramming in glioma.","date":"2025","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40933894","citation_count":0,"is_preprint":false},{"pmid":"41511661","id":"PMC_41511661","title":"Downregulation of NFIA facilitates glycolysis, histone lactylation, and activation of the FN1-integrin α5β1 pathway in pancreatic cancer.","date":"2026","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/41511661","citation_count":0,"is_preprint":false},{"pmid":"37533740","id":"PMC_37533740","title":"Hsa-miR-223-3p participates in the process of anthracycline-induced cardiomyocyte damage by regulating NFIA gene.","date":"2023","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/37533740","citation_count":0,"is_preprint":false},{"pmid":"41408833","id":"PMC_41408833","title":"Biochemical and structural studies of NFIA and NFIC reveal a conserved mechanism for specific DNA recognition and provide insight into potential pathogenicity of disease-associated mutations.","date":"2025","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/41408833","citation_count":0,"is_preprint":false},{"pmid":"40266456","id":"PMC_40266456","title":"Generation of human induced pluripotent stem cell lines derived from a patient carrying an intragenic deletion in the NFIA gene.","date":"2025","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/40266456","citation_count":0,"is_preprint":false},{"pmid":"39996378","id":"PMC_39996378","title":"A Case of Prenatal Diagnosis of NFIA -Related Disorder Indicated by Noninvasive Prenatal Testing.","date":"2025","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/39996378","citation_count":0,"is_preprint":false},{"pmid":"42036008","id":"PMC_42036008","title":"Clinical significance and biological role of miR-592 in diabetic retinopathy via targeted negative regulation of NFIA.","date":"2026","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/42036008","citation_count":0,"is_preprint":false},{"pmid":"29485116","id":"PMC_29485116","title":"PAX6 can substitute for LHX2 and override NFIA-induced astrogliogenesis in developing hippocampus in vivo.","date":"2018","source":"Journal of biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/29485116","citation_count":0,"is_preprint":false},{"pmid":"42158426","id":"PMC_42158426","title":"The NFIA::CBFA2T3 identifies a molecularly defined subgroup of acute erythroid leukemia/erythroid sarcoma.","date":"2026","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/42158426","citation_count":0,"is_preprint":false},{"pmid":"40606574","id":"PMC_40606574","title":"Detection of a new heterozygous pathogenic NFIA variant in metopic craniosynostosis with preaxial polysyndactyly: A case report.","date":"2025","source":"JPRAS open","url":"https://pubmed.ncbi.nlm.nih.gov/40606574","citation_count":0,"is_preprint":false},{"pmid":"42205757","id":"PMC_42205757","title":"Identification of an NFIA::CBFA2T3 fusion in cerebrospinal fluid confirms the diagnosis of pediatric CNS myeloid sarcoma with erythroid differentiation: a case report and literature review.","date":"2026","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/42205757","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.26.25336314","title":"Increased plasma fibronectin mirrors intimal phenotypic switching of vascular smooth muscle cells in moyamoya arteriopathy","date":"2025-10-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.26.25336314","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.11.647869","title":"Loss of CARM1 alters the developmental programming of Glioma stem-like cells and creates a druggable NGFR/NTRK dependency","date":"2025-04-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.11.647869","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.09.25327290","title":"Tracing the Benign Nature of Pilocytic Astrocytoma with a Focus on How Gliogenic Regulators Impact its Tumorigenesis: a systematic review","date":"2025-05-09","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.09.25327290","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.26.600888","title":"Spinal motor neuron development and metabolism are transcriptionally regulated by Nuclear Factor IA","date":"2024-06-26","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.26.600888","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.26.24311074","title":"Epigenome-wide characterization reveals aberrant DNA methylation of host genes regulating CD4+ T cell HIV-1 reservoir size in women with HIV","date":"2024-07-27","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.26.24311074","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49329,"output_tokens":8614,"usd":0.138599,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18579,"output_tokens":6787,"usd":0.131285,"stage2_stop_reason":"end_turn"},"total_usd":0.269884,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"NFI-A (NFIA) competes with C/EBPalpha for binding to the miR-223 promoter: NFIA maintains miR-223 at low levels, whereas C/EBPalpha replaces NFIA upon retinoic acid-induced differentiation to upregulate miR-223 expression. Additionally, miR-223 represses NFIA translation, forming a negative-feedback loop that controls granulopoiesis. RNAi against NFIA and ectopic miR-223 both enhance granulocytic differentiation in APL cells.\",\n      \"method\": \"Promoter competition assay, RNAi knockdown, ectopic expression, translational reporter assays in APL cells\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional experiments (RNAi, OE, reporter assays), multiple orthogonal methods in a single rigorous study, widely replicated\",\n      \"pmids\": [\"16325577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NFIA is necessary and sufficient for induction of the glial marker GLAST in spinal cord ventricular zone progenitors, is required for continued inhibition of neurogenesis via HES5 (a Notch effector), and promotes migration and differentiation of astrocyte precursors. Loss of NFIA in the spinal cord prevents gliogenesis onset.\",\n      \"method\": \"In vivo loss-of-function (knockout mice), gain-of-function electroporation, immunofluorescence, gene expression analysis\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout plus gain-of-function with defined cellular and molecular phenotypes, replicated across labs\",\n      \"pmids\": [\"17178400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Disruption of the murine Nfia gene causes agenesis of the corpus callosum and hydrocephalus, establishing NFIA as essential for corpus callosum formation and forebrain development.\",\n      \"method\": \"Gene knockout (homologous recombination), histology, behavioral assessment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined developmental phenotype, replicated by multiple subsequent studies\",\n      \"pmids\": [\"10518556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NFIA is expressed in midline glial structures (glial wedge, indusium griseum, glial sling) of developing forebrain. In Nfia−/− mice, sling cells migrate aberrantly, midline glia are absent, Slit2 expression is reduced, and callosal axons fail to cross the midline, establishing NFIA as required for midline glia formation and commissural axon guidance.\",\n      \"method\": \"Immunohistochemistry, in situ hybridization, Nfia knockout mice, axon tracing\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct loss-of-function in KO mice with specific cellular and molecular phenotypes, multiple orthogonal methods\",\n      \"pmids\": [\"12514217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NFIA downregulates the Notch effector Hes1 in telencephalic progenitors, thereby repressing progenitor self-renewal while simultaneously activating astrocyte-specific gene expression. NFIA thus links repression of self-renewal to activation of differentiation.\",\n      \"method\": \"Loss-of-function in vivo (Nfia KO mice), promoter reporter assays, gene expression analysis, chromatin immunoprecipitation\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mice combined with promoter assays and epistasis establishing NFIA→Hes1 repression, replicated across labs\",\n      \"pmids\": [\"20610746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Sox9 induces NFIA expression to initiate gliogenesis. Sox9 and NFIA then form a protein complex and co-regulate downstream glial genes including Apcdd1 (migration) and Mmd2 (metabolism). This defines a Sox9→NFIA transcriptional cascade for glial lineage commitment.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, in vivo electroporation, loss-of-function mouse genetics, gene expression analysis\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP demonstrating Sox9-NFIA complex, ChIP-seq, in vivo genetics, multiple orthogonal methods\",\n      \"pmids\": [\"22500632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NFIA directly binds and activates the beta-globin promoter while directly binding and repressing the G-CSF receptor promoter in hematopoietic progenitor cells, thereby directing progenitor fate toward the erythroid vs. granulocytic lineage.\",\n      \"method\": \"Chromatin immunoprecipitation, reporter assays, gain- and loss-of-function in unilineage and bilineage hematopoietic progenitor cultures\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct promoter binding (ChIP) combined with functional gain/loss-of-function assays showing lineage redirection\",\n      \"pmids\": [\"19542302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NFIA co-localizes with PPARγ at brown-fat-specific enhancers; NFIA binding precedes and facilitates PPARγ binding, increasing chromatin accessibility and activating brown-fat gene transcription. NFIA-knockout brown fat shows impaired expression of brown-fat-specific genes and reciprocal elevation of muscle genes. Introduction of NFIA into myoblasts drives brown adipocyte differentiation.\",\n      \"method\": \"Genome-wide open chromatin analysis (ATAC-seq), ChIP-seq, NFIA knockout mice, lentiviral NFIA overexpression in myoblasts\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genome-wide chromatin analysis, KO mice, gain-of-function, multiple orthogonal methods in one study\",\n      \"pmids\": [\"28812581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The C-terminal 17 amino acid residues of NFIA (pro#3 domain) are required for its transcriptional activity; this domain mediates chromatin penetration and binding to the Pparg enhancer to activate adipogenesis. Separately, a pro#3-domain-independent mechanism allows NFIA to bind the Myod1 enhancer and repress MyoD expression by competing with KLF5, suppressing the myogenic gene program.\",\n      \"method\": \"Deletion mutagenesis, ChIP-seq, NFIA-KO cell rescue experiments, reporter assays\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — domain mutagenesis combined with ChIP-seq and KO rescue, multiple orthogonal methods in single study\",\n      \"pmids\": [\"32991581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NFIA promotes endocrine cell fate in pancreatic progenitors by transcriptionally repressing Mib1 (an E3 ubiquitin ligase targeting Dll1 for endocytosis), thereby limiting Dll1 internalization and restraining Notch activation to allow neurogenin-3 expression. Pancreatic deletion of NFIA increases duct and decreases endocrine formation; Mib1 knockdown rescues the cell fate defects.\",\n      \"method\": \"Pancreas-specific NFIA knockout mice, ectopic NFIA expression in human pancreatic progenitors, ChIP for NFIA binding at Mib1 promoter, Dll1 endocytosis assay, epistasis (Mib1 KD rescue)\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ChIP showing NFIA at Mib1 promoter, KO mice, human progenitor gain-of-function, genetic rescue epistasis\",\n      \"pmids\": [\"30590051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NFIA in adipocytes upregulates oxidative phosphorylation genes by facilitating PPARγ genomic binding at enhancers and directly binds the regulatory region of the Ccl2 gene to repress MCP-1 transcription, thereby suppressing adipose tissue inflammation and improving glucose homeostasis.\",\n      \"method\": \"Adipocyte-specific NFIA transgenic mice, ChIP-seq, enhancer activation assays, glucose tolerance tests\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic model, ChIP-seq showing direct NFIA binding at Ccl2 regulatory region, multiple orthogonal methods\",\n      \"pmids\": [\"37487068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"During sepsis, NFIA transcriptionally represses the cyclin-dependent kinase inhibitor p21, arresting differentiation of Gr1+CD11b+ myeloid progenitors to generate immunosuppressive MDSCs. Knockdown of NFIA restores p21 expression and promotes monocyte/dendritic cell differentiation; ectopic NFIA in normal Gr1+CD11b+ cells generates an immunosuppressive phenotype.\",\n      \"method\": \"Gain- and loss-of-function (ectopic expression and siRNA knockdown), gene expression analysis, ex vivo differentiation assays in septic mouse myeloid cells\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional gain/loss-of-function with defined molecular target (p21), single lab, multiple assays\",\n      \"pmids\": [\"26259914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Conditional myeloid-specific deletion of Nfia prevents MDSC expansion during sepsis; NFI-A-deficient Gr1+CD11b+ cells differentiate normally into macrophages and dendritic cells and are not immunosuppressive. Ectopic NFI-A expression in myeloid progenitors from Nfia-deficient mice restores MDSC phenotype. NFIA and miR-21/miR-181b form a mutual regulatory loop sustaining MDSC immunosuppression.\",\n      \"method\": \"Conditional myeloid knockout (LysM-Cre × Nfia-flox), ectopic NFI-A expression, ex vivo differentiation assays, cecal ligation and puncture sepsis model\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with defined phenotype, gain-of-function rescue, replicated across multiple sepsis studies\",\n      \"pmids\": [\"28167668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NFI-A proteins (identified via mass spectrometry after DNA-affinity purification from rat olfactory mucosa) bind the NPTA element in the CYP2A3 promoter and transactivate the gene in vitro. A novel alternative-splice isoform, NFI-A-short, lacks the transactivation domain and counteracts activation by full-length NFI-A2. ChIP demonstrates NFI association with the CYP2A3 promoter in olfactory mucosa but not in liver, where the promoter is hypermethylated.\",\n      \"method\": \"DNA-affinity purification, mass spectrometry, transient transfection reporter assay, chromatin immunoprecipitation (ChIP), alternative splicing analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution (reporter assay + mutagenesis-equivalent isoform comparison), ChIP in vivo, mass spec identification; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"15123731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NFI-A1 activates transcription through the CEREM enhancer element of the UGT1A2 promoter; NFI-C1 has an inhibitory effect and suppresses NFI-A1-mediated activation in a concentration-dependent manner through heterodimerization competition at CEREM.\",\n      \"method\": \"Affinity chromatography, immunoblot with isoform-specific antibodies, co-expression reporter gene assay in cultured hepatocytes\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assay with co-expression of NFI isoforms, single lab, two methods\",\n      \"pmids\": [\"16169882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"An NFIA:RAF1 fusion arising from chromosomal rearrangement results in constitutive Raf1 kinase activity, activates the MEK1/2 cascade, and promotes cancer cell proliferation. The NFIA:RAF1 fusion localizes to the plasma membrane (distinct from nuclear WT-NFIA and cytoplasmic WT-Raf1), indicating that NFIA sequences drive membrane targeting of the oncogenic fusion.\",\n      \"method\": \"RNA sequencing (fusion detection), kinase activity assay, MEK phosphorylation immunoblot, subcellular localization (immunofluorescence), cell proliferation assay\",\n      \"journal\": \"Cancer genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional kinase assay, subcellular localization, downstream signaling, single lab, multiple methods\",\n      \"pmids\": [\"27810072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NFIA activates NFκB p65 transcription and protein levels in glioblastoma cells; NFκB in turn activates the NFIA promoter, forming a feed-forward loop. NFIA-driven NFκB activation is required for upregulation of anti-apoptotic factors TRAF1 and cIAPs. NFIA knockdown decreases NFκB and increases baseline apoptosis; NFκB inhibition reverses the NFIA anti-apoptotic effect.\",\n      \"method\": \"Gain- and loss-of-function (knockdown/overexpression), gene expression analysis, apoptosis assays, epistasis by NFκB inhibitor rescue in patient-derived GBM cells\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal transcriptional regulation established with functional epistasis, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"27994064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Sox9 and Isl1-Lhx3 regulate long-range enhancer activity to control NFIA expression in glial and neuronal populations in the spinal cord, respectively. These enhancers and transcription factors form distinct chromatin architectures (assessed by chromatin conformation analysis) in glial vs. neuronal lineages. In glioma models, the glia-specific chromatin architecture is preserved and these enhancers are required for NFIA expression and glioma formation.\",\n      \"method\": \"Enhancer reporter assays in vivo, chromatin conformation capture, genetic deletion of enhancers, glioma mouse models\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — chromatin conformation analysis, in vivo enhancer deletion, glioma functional studies; single lab but multiple orthogonal high-resolution methods\",\n      \"pmids\": [\"28892058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NFIA directly regulates astrocytic TRPV4 expression; loss of NFIA inhibits TRPV4 upregulation, weakens astrocytic calcium activity and specific astrocyte reactivity, and suppresses seizure activity in a 4-AP epilepsy model. ChIP was used to identify NFIA binding at the TRPV4 regulatory region.\",\n      \"method\": \"RNAi knockdown of NFIA in vivo, NFIA overexpression (HA-tagged plasmid), ChIP for NFIA at TRPV4 promoter, calcium imaging, EEG seizure recording\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP showing NFIA at TRPV4 regulatory region, functional loss/gain-of-function with physiological readout, single lab\",\n      \"pmids\": [\"37880726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Transient NFIA expression is sufficient to trigger glial competency of human pluripotent stem cell-derived neural stem cells within 5 days, involving rapid but reversible chromatin remodeling, GFAP promoter demethylation, and lengthening of the G1 cell cycle phase. Genetic or pharmacological G1 length manipulation partially mimics NFIA function.\",\n      \"method\": \"Lentiviral NFIA overexpression in human PSC-derived NSCs, ATAC-seq, bisulfite sequencing, cell cycle analysis, pharmacological G1 manipulation\",\n      \"journal\": \"Nature biotechnology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genome-wide chromatin remodeling assay, DNA methylation analysis, cell cycle experiments, functional differentiation assays, multiple orthogonal methods\",\n      \"pmids\": [\"30804533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Sox8 is a direct transcriptional target of Nfia at the initiation of the gliogenic phase. Sox8 augments LIF-induced astrocytic differentiation by associating with STAT3 through transcriptional coactivator p300 (without inducing Gfap DNA demethylation, unlike Nfia itself). Sox8 knockdown inhibits Nfia-enhanced astrocytic differentiation.\",\n      \"method\": \"ChIP showing NFIA at Sox8 regulatory elements, Sox8 siRNA knockdown, Co-IP of Sox8 with STAT3 and p300, Gfap methylation analysis, differentiation assays\",\n      \"journal\": \"Pharmacology research & perspectives\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and Co-IP establishing direct regulatory relationship, single lab, multiple methods\",\n      \"pmids\": [\"34677001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The NFIA-ETO2 fusion protein (from t(1;16)(p31;q24)) blocks erythroid differentiation by preferentially binding and repressing erythroid genes containing NFI binding sites and ETO2-decorated sites, shifting transcriptional activity from GATA- to ETS-motif-containing target genes. NFIA-ETO2 alone does not induce disease, but cooperates with TP53R248Q mutation to induce a fully penetrant transplantable pure erythroid leukemia in mice.\",\n      \"method\": \"Murine erythroblast retroviral expression, primary fetal liver EB cultures, transplantation assay, ChIP-seq, RNA-seq, motif analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq, RNA-seq, in vivo transplantation, genetic epistasis with TP53 mutation, multiple orthogonal methods\",\n      \"pmids\": [\"36735909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NFIA and NFIB are co-expressed in developing cortex and can form heterodimers in vivo (demonstrated by co-immunoprecipitation). Compound homozygous knockout of both genes produces a more severe cortical phenotype than single knockouts, indicating additive function. Shared differentially regulated target genes are enriched for NFI binding sites in their promoters.\",\n      \"method\": \"Co-immunoprecipitation, compound knockout mouse genetics, RNA-seq, ChIP-seq\",\n      \"journal\": \"Brain and neuroscience advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrating heterodimerization, compound KO genetics, single lab, multiple methods\",\n      \"pmids\": [\"32166136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The NFIA missense variant K125E is a loss-of-function allele: ectopic wild-type NFIA in Drosophila causes developmental defects not seen with K125E-NFIA; wild-type human NFIA rescues commissural axon defects in nfia-deficient zebrafish but K125E does not; K125E impairs transcriptional regulation of the HES1 promoter in cultured cells.\",\n      \"method\": \"Drosophila ectopic expression assay, zebrafish nfia morphant rescue, HES1 promoter luciferase reporter assay\",\n      \"journal\": \"American journal of medical genetics. Part A\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — two independent in vivo model organisms plus in vitro reporter assay, multiple orthogonal methods establishing LOF\",\n      \"pmids\": [\"33973697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Crystal structures of NFIC homodimer and NFIA/NFIC monomers lacking their dimerization region in complex with double-stranded DNA reveal that NFI proteins recognize a dyad-symmetric TGGCA(N3)TGCCA sequence motif. Dimerization enhances both DNA-binding affinity and specificity. Mutagenesis and binding assays validate key residues in protein-DNA interaction. Disease-associated mutations are shown to impair DNA binding.\",\n      \"method\": \"X-ray crystallography, mutagenesis, in vitro DNA-binding affinity assays (EMSA/ITC), structural analysis\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures of NFIA/NFIC-DNA complexes with mutagenesis validation; single study but Tier 1 methods with orthogonal binding assays\",\n      \"pmids\": [\"41408833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In OA articular chondrocytes, NFIA upregulation drives increased fatty acid synthesis and oxidation by transcriptionally activating ACACA and CPT2. Inhibition of NFIA suppresses these metabolic enzymes and restores cellular homeostasis in murine and human OA chondrocytes.\",\n      \"method\": \"Multi-omics (RNA-seq, ATAC-seq, MRE-seq, metabolomics), NFIA inhibition in murine/human OA chondrocytes, gene expression analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-omics linking NFIA to chromatin accessibility at metabolic gene loci, functional NFIA inhibition experiments, single study\",\n      \"pmids\": [\"40737429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NFIA directly represses transcription of the glycolytic enzyme PKM in pancreatic cancer cells, thereby attenuating glycolysis. NFIA also transcriptionally suppresses FN1 expression. Loss of NFIA leads to increased glycolysis, histone lactylation, epigenetic upregulation of FN1, and activation of integrin α5β1-FAK-PI3K-Akt signaling.\",\n      \"method\": \"NFIA overexpression/knockdown, ChIP showing direct NFIA binding at PKM and FN1 promoters, glucose uptake/lactate assays, histone lactylation analysis, signaling pathway western blots\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP at PKM and FN1 promoters, functional metabolic assays, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"41511661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NFIA directly binds two motifs in the SMC4 promoter (-1379 bp and -354 bp) to drive SMC4 transcription in glioma cells, as validated by dual-luciferase and ChIP assays. SMC4 promotes metastasis via TGF-β/SMAD signaling and aerobic glycolysis via LDHA.\",\n      \"method\": \"Dual-luciferase reporter assay, ChIP assay for NFIA at SMC4 promoter, NFIA and SMC4 gain/loss-of-function in glioma cell lines, xenograft and tail-vein metastasis models\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP and luciferase assay confirming NFIA-SMC4 promoter binding, functional downstream assays, single lab\",\n      \"pmids\": [\"40933894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NFIA represses S100A7 expression by directly binding the S100A7 promoter (validated by ChIP and dual-luciferase assay), reducing inflammation and apoptosis of keratinocytes in oral lichen planus. NFIA overexpression ameliorates OLP inflammation in vivo, an effect reversed by S100A7 overexpression.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, shRNA knockdown, in vivo OLP mouse model, ELISA, flow cytometry\",\n      \"journal\": \"The Kaohsiung journal of medical sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP and luciferase establishing NFIA binding at S100A7 promoter, in vivo rescue experiments, single lab\",\n      \"pmids\": [\"40560736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NFIA determines allele-specific Ucp1 expression in beige adipocytes: the alternative T allele of rs47238345 at the Ucp1 -12kb enhancer in 129 mice facilitates allele-specific NFIA binding, which mediates allele-specific enhancer-promoter looping and Ucp1 transcription. CRISPR-mediated SNP editing of rs47238345 increases Ucp1 expression.\",\n      \"method\": \"Allele-specific ChIP, chromatin conformation assay (enhancer-promoter interaction), CRISPR-Cas9/Cpf1 SNP editing, allele-specific expression analysis\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — allele-specific ChIP, chromatin looping assay, and CRISPR causal editing establish direct mechanistic link between NFIA binding and Ucp1 expression\",\n      \"pmids\": [\"35874098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In Nfia conditional knockout retinas, AII amacrine cells are massively and selectively absent. Type 2 cone bipolar cells (which are interconnected to AII cells) are also partially reduced, with their loss occurring after AII cell loss, indicating a dependency relationship. Nfia loss results in profound diminishment of oscillatory potentials in the ERG.\",\n      \"method\": \"Conditional knockout mice (Nfia-CKO), cell counting, ERG electrophysiology, temporal deletion (postnatal)\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with precise temporal control, defined cellular and physiological phenotypes, epistasis between cell populations\",\n      \"pmids\": [\"37775301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Astrocyte-derived extracellular vesicles (ADEVs) from obese/high-glucose-stimulated astrocytes are enriched in NFIA protein and are taken up by hippocampal neurons, causing synaptic injury and cognitive impairment. Astrocyte-specific knockdown of Nfia reduces NFIA in ADEVs and ameliorates synaptic dysfunction and cognitive impairment in obese mice.\",\n      \"method\": \"Proteomics of brain-derived EVs, AAV-mediated astrocyte-specific Nfia knockdown, ADEV isolation/administration, behavioral tests, synaptic protein analysis\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KD with defined behavioral/synaptic phenotype, proteomic identification, in vivo ADEV transfer experiments; single lab\",\n      \"pmids\": [\"40448146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NFIA is required for motor neuron positioning, axonal branching, and neuromuscular junction formation in the spinal cord. NFIA is also required for proper mitochondrial function and ATP production in motor neurons, linking transcriptional regulation to metabolic function during motor circuit development.\",\n      \"method\": \"Conditional knockout mice, immunofluorescence, axon tracing, neuromuscular junction analysis, mitochondrial function assays (OCR/ATP production)\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined cellular and metabolic phenotypes; preprint, single lab\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CARM1 methylates NFIA (NFIA is a CARM1 substrate), and this CARM1/NFIA relationship represses NGFR signaling in glioma stem-like cells; loss of CARM1 dysregulates NFIA function and leads to increased NGFR/NTRK dependency.\",\n      \"method\": \"Multi-omics (proteomics + transcriptomics), CARM1 depletion, NFIA overexpression epistasis, NFIA-CARM1 substrate identification\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, single lab, substrate identification without in vitro reconstitution of methylation; mechanistic model proposed from indirect evidence\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"NFIA is a dimeric transcription factor that recognizes dyad-symmetric TGGCA(N3)TGCCA DNA motifs (established by crystal structure) and functions as a context-dependent transcriptional activator or repressor: in the nervous system it drives gliogenesis by activating glial genes, repressing the Notch effector Hes1, and forming a complex with Sox9; in adipose tissue it facilitates PPARγ binding at brown-fat enhancers to activate thermogenic and oxidative phosphorylation programs while directly repressing inflammatory genes such as Ccl2; in hematopoiesis it directly activates beta-globin and represses the G-CSF receptor to bias progenitors toward erythroid vs. granulocytic fate, and it sustains immunosuppressive MDSCs by repressing p21; in the pancreas it represses Mib1 to restrain Dll1 endocytosis and Notch activation, promoting endocrine fate; and in multiple cancers oncogenic NFIA fusions (NFIA-ETO2, NFIA-RAF1) drive disease through dominant gain-of-function mechanisms.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NFIA is a dimeric, sequence-specific transcription factor that acts as a context-dependent activator or repressor to control lineage commitment across the nervous system, blood, and adipose tissue [#1, #6, #7]. It recognizes a dyad-symmetric TGGCA(N3)TGCCA motif, and dimerization enhances both its DNA-binding affinity and specificity [#24]. In the developing CNS, NFIA is a master gliogenic switch: it is induced by Sox9 and forms a Sox9–NFIA protein complex to drive astrocyte gene programs, while repressing Notch effectors Hes1/Hes5 to terminate progenitor self-renewal and initiate differentiation [#1, #4, #5]; its activity depends on long-range enhancers regulated by Sox9 and Isl1-Lhx3 [#17], and transient NFIA expression alone confers glial competency through reversible chromatin remodeling and GFAP promoter demethylation [#19]. Loss of NFIA in mice causes corpus callosum agenesis and hydrocephalus through failure of midline glia formation and commissural axon guidance, and a K125E loss-of-function variant impairs HES1 regulation and recapitulates these defects in model organisms [#2, #3, #23]. In adipocytes, NFIA binds brown-fat and beige enhancers ahead of PPARγ to increase chromatin accessibility and activate thermogenic and oxidative-phosphorylation genes, while directly repressing the inflammatory chemokine gene Ccl2 [#7, #10, #29]; a C-terminal pro#3 domain mediates this enhancer-penetrating activation, whereas a separate domain-independent mode lets NFIA repress Myod1 by competing with KLF5 [#8]. In hematopoiesis NFIA biases progenitor fate by activating beta-globin and repressing the G-CSF receptor [#6], and in pancreatic progenitors it represses the E3 ligase Mib1 to restrain Dll1 endocytosis and Notch activation, promoting endocrine fate [#9]. NFIA also sustains immunosuppressive myeloid-derived suppressor cells during sepsis by repressing the cell-cycle inhibitor p21 [#11, #12]. In disease, oncogenic NFIA fusions act through gain-of-function: NFIA-RAF1 drives constitutive RAF/MEK signaling from the plasma membrane [#15], and NFIA-ETO2 represses erythroid genes and cooperates with mutant TP53 to drive erythroleukemia [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established at the organismal level that NFIA is essential for forebrain development, defining a genetic requirement before its molecular targets were known.\",\n      \"evidence\": \"Nfia gene knockout in mice with histology and behavioral assessment\",\n      \"pmids\": [\"10518556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify direct transcriptional targets\", \"Cellular basis of the corpus callosum phenotype unresolved at this stage\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved the cellular basis of the developmental phenotype by showing NFIA is required for midline glia formation and Slit2-dependent commissural axon guidance.\",\n      \"evidence\": \"Immunohistochemistry, in situ hybridization, axon tracing in Nfia knockout mice\",\n      \"pmids\": [\"12514217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Slit2 is a direct NFIA target not established\", \"Molecular mechanism of glial specification not yet defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified NFIA biochemically as a sequence-specific transactivator and revealed isoform diversity, with a short splice variant lacking the transactivation domain acting as a dominant counter-regulator.\",\n      \"evidence\": \"DNA-affinity purification, mass spectrometry, reporter assays, and ChIP in rat olfactory mucosa\",\n      \"pmids\": [\"15123731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological role of NFI-A-short isoform in vivo unknown\", \"Tissue-specific promoter methylation control of NFIA targets not generalized\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined a mechanistic role for NFIA in granulopoiesis through a competitive promoter switch with C/EBPalpha and a miR-223 negative-feedback loop, framing NFIA as a tunable lineage gatekeeper.\",\n      \"evidence\": \"Promoter competition, RNAi, ectopic expression, and translational reporters in APL cells\",\n      \"pmids\": [\"16325577\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address NFIA in erythroid fate\", \"Structural basis of NFIA/C/EBPalpha competition not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated NFIA is necessary and sufficient for gliogenesis onset, coupling glial gene activation to continued Notch-mediated repression of neurogenesis.\",\n      \"evidence\": \"In vivo knockout and gain-of-function electroporation in spinal cord progenitors\",\n      \"pmids\": [\"17178400\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream inducers of NFIA not yet identified\", \"Direct vs indirect regulation of HES5 unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed NFIA directly and oppositely regulates two lineage promoters (beta-globin activation, G-CSFR repression) to redirect hematopoietic progenitor fate, establishing dual activator/repressor function on direct targets.\",\n      \"evidence\": \"ChIP, reporter assays, gain/loss-of-function in hematopoietic progenitor cultures\",\n      \"pmids\": [\"19542302\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors determining activation vs repression not identified\", \"Chromatin context dictating bivalent behavior unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Unified NFIA's dual activity by showing it represses Hes1 to block self-renewal while activating astrocyte genes, linking the two arms of differentiation control.\",\n      \"evidence\": \"Nfia knockout mice, promoter reporters, and ChIP in telencephalic progenitors\",\n      \"pmids\": [\"20610746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism distinguishing repressive vs activating complexes not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed NFIA in a Sox9→NFIA cascade and demonstrated direct Sox9–NFIA complex formation co-regulating glial migration and metabolic genes.\",\n      \"evidence\": \"Co-IP, ChIP-seq, in vivo electroporation, and mouse genetics\",\n      \"pmids\": [\"22500632\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of the Sox9-NFIA interface unknown\", \"Genome-wide division of labor between Sox9 and NFIA incomplete\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended NFIA's repressor role to innate immunity, showing it represses p21 to arrest myeloid differentiation and generate immunosuppressive MDSCs during sepsis.\",\n      \"evidence\": \"Gain/loss-of-function and ex vivo differentiation in septic mouse myeloid cells\",\n      \"pmids\": [\"26259914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab functional data without in vivo conditional deletion at this stage\", \"Direct ChIP at p21 promoter not shown here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established NFIA as a pioneer-like factor in brown fat that binds enhancers ahead of PPARγ to open chromatin and activate the thermogenic program, demonstrating a chromatin-priming mechanism.\",\n      \"evidence\": \"ATAC-seq, ChIP-seq, knockout mice, and myoblast overexpression\",\n      \"pmids\": [\"28812581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NFIA binds nucleosomal DNA as a bona fide pioneer factor not directly tested\", \"Cofactors recruited to open enhancers undefined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Confirmed and mechanistically anchored the MDSC role with myeloid-specific conditional deletion and a NFIA–miR-21/miR-181b regulatory loop sustaining immunosuppression.\",\n      \"evidence\": \"LysM-Cre × Nfia-flox conditional knockout, rescue, and CLP sepsis model\",\n      \"pmids\": [\"28167668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct microRNA-NFIA promoter interactions not fully mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed lineage-specific long-range enhancer architecture controlling NFIA expression in glia versus neurons, and showed glioma exploits the glial enhancer configuration.\",\n      \"evidence\": \"In vivo enhancer reporters, chromatin conformation capture, enhancer deletion, glioma mouse models\",\n      \"pmids\": [\"28892058\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Sox9 vs Isl1-Lhx3 select distinct enhancers not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified an NFIA-driven feed-forward NF\\u03baB loop conferring anti-apoptotic survival in glioblastoma, expanding NFIA into a pro-tumor transcriptional circuit.\",\n      \"evidence\": \"Knockdown/overexpression, apoptosis assays, and NF\\u03baB inhibitor epistasis in patient-derived GBM cells\",\n      \"pmids\": [\"27994064\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NFIA binds the p65 promoter directly not shown\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a non-cell-autonomous Notch control mechanism whereby NFIA represses Mib1 to limit Dll1 endocytosis and promote pancreatic endocrine fate, with genetic rescue establishing causality.\",\n      \"evidence\": \"Pancreas-specific knockout, human progenitor gain-of-function, ChIP, and Mib1-knockdown epistasis\",\n      \"pmids\": [\"30590051\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors mediating Mib1 repression not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated NFIA is sufficient to confer human glial competency via rapid reversible chromatin remodeling, GFAP demethylation, and G1 lengthening, linking cell-cycle state to epigenetic licensing.\",\n      \"evidence\": \"Lentiviral NFIA in human PSC-derived NSCs, ATAC-seq, bisulfite sequencing, cell-cycle and pharmacological assays\",\n      \"pmids\": [\"30804533\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal chain between G1 lengthening and chromatin opening incompletely separated\", \"How NFIA directs demethylation machinery unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapped distinct domains for NFIA's opposing activities: a C-terminal pro#3 domain for enhancer-penetrating activation of Pparg, and a domain-independent KLF5-competitive mechanism for Myod1 repression.\",\n      \"evidence\": \"Deletion mutagenesis, ChIP-seq, and knockout rescue in adipogenic cells\",\n      \"pmids\": [\"32991581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of chromatin penetration by pro#3 domain unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed NFIA forms heterodimers with NFIB in cortex and acts additively, indicating combinatorial NFI control of shared targets.\",\n      \"evidence\": \"Co-IP, compound knockout genetics, RNA-seq, ChIP-seq\",\n      \"pmids\": [\"32166136\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences of heterodimer vs homodimer not separated\", \"Single-lab data\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified Sox8 as a direct NFIA target that amplifies astrocytic differentiation through STAT3/p300, extending the gliogenic cascade downstream of NFIA.\",\n      \"evidence\": \"ChIP, Sox8 knockdown, Co-IP of Sox8 with STAT3/p300, methylation analysis\",\n      \"pmids\": [\"34677001\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Relative contribution of Sox8 vs other targets to gliogenesis unquantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked NFIA to astrocyte physiology by showing it directly regulates TRPV4 to control astrocytic calcium activity and seizure susceptibility.\",\n      \"evidence\": \"In vivo RNAi/overexpression, ChIP, calcium imaging, EEG in a 4-AP epilepsy model\",\n      \"pmids\": [\"37880726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Whether the effect is purely transcriptional not fully isolated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established NFIA K125E as a disease-causing loss-of-function allele through cross-species rescue failure and impaired HES1 regulation, connecting NFIA dysfunction to human developmental disease.\",\n      \"evidence\": \"Drosophila ectopic expression, zebrafish morphant rescue, HES1 luciferase reporter\",\n      \"pmids\": [\"33973697\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full spectrum of patient phenotypes not mechanistically mapped\", \"Structural impact of K125E on DNA binding not resolved here\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided causal evidence that allele-specific NFIA binding at a Ucp1 enhancer SNP controls enhancer-promoter looping and thermogenic gene expression, demonstrating NFIA's role in 3D enhancer regulation.\",\n      \"evidence\": \"Allele-specific ChIP, chromatin conformation, CRISPR SNP editing in beige adipocytes\",\n      \"pmids\": [\"35874098\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Looping machinery recruited by NFIA not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the NFIA-ETO2 fusion oncomechanism, showing it redirects transcription from GATA to ETS targets and cooperates with mutant TP53 to drive pure erythroleukemia.\",\n      \"evidence\": \"Murine erythroblast expression, ChIP-seq, RNA-seq, transplantation, TP53 epistasis\",\n      \"pmids\": [\"36735909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the fusion's repressive activity requires native NFIA partners unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed NFIA improves metabolic homeostasis in adipose tissue by facilitating PPARγ-driven oxidative phosphorylation genes and directly repressing the inflammatory chemokine Ccl2.\",\n      \"evidence\": \"Adipocyte-specific transgenic mice, ChIP-seq, glucose tolerance tests\",\n      \"pmids\": [\"37487068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors mediating Ccl2 repression not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed a selective cell-type requirement for NFIA in retinal AII amacrine cell generation, with dependent loss of interconnected bipolar cells and impaired retinal physiology.\",\n      \"evidence\": \"Temporally controlled conditional knockout, cell counting, ERG\",\n      \"pmids\": [\"37775301\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct retinal NFIA targets not identified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Provided the structural basis for NFI DNA recognition, showing dyad-symmetric motif binding and dimerization-enhanced affinity/specificity, and rationalizing how disease mutations impair DNA binding.\",\n      \"evidence\": \"X-ray crystallography of NFIA/NFIC-DNA complexes with mutagenesis and binding assays\",\n      \"pmids\": [\"41408833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length NFIA structure with transactivation domains not determined\", \"Structures with cofactors absent\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Expanded NFIA into metabolic regulation in disease, showing it controls fatty acid metabolism in osteoarthritic chondrocytes and represses glycolysis/FN1 in pancreatic cancer.\",\n      \"evidence\": \"Multi-omics and NFIA inhibition in OA chondrocytes; ChIP and metabolic assays in pancreatic cancer cells\",\n      \"pmids\": [\"40737429\", \"41511661\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Context-dependent direction of metabolic regulation not reconciled\", \"Single-lab studies\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How NFIA's bidirectional activator/repressor output is selected at each locus — through specific cofactor recruitment, post-translational modification, and chromatin context — remains incompletely defined.\",\n      \"evidence\": \"No single study in the corpus resolves the cofactor/modification code governing activation vs repression\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Cofactor partners that toggle NFIA between activation and repression unidentified\", \"Role of post-translational modification (e.g. methylation) in activity switching unproven\", \"Genome-wide rules predicting target outcome lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 4, 6, 7, 8, 9, 10, 24]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [24, 6, 9, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [15, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 2, 3, 4, 5, 30]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 9, 10, 24]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [7, 19, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [15, 21, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SOX9\", \"NFIB\", \"PPARG\", \"NFIC\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}